United Therapeutics Corporation Operating Cash Flow
United Therapeutics Corporation (UTHR) reported Operating Cash Flow of $776.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- United Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $313.60M, a 63.59% increase year-over-year.
- United Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $463.30M, a 0.46% increase year-over-year.
- United Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $346.20M, a 1.47% increase year-over-year.
- United Therapeutics Corporation net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $562.10M, a 49.02% increase year-over-year.
- United Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2025 was $1.56B, a 17.64% increase from fiscal 2024.
- United Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2024 was $1.33B, a 35.70% increase from fiscal 2023.
- United Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2023 was $978.00M, a 21.87% increase from fiscal 2022.
- United Therapeutics Corporation net cash provided by (used in) operating activities for fiscal 2022 was $802.50M, a 34.15% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $313.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $776.90M 10-Q · filed 2026-08-05 | $1.12B derived: sum of 3 quarters · filed 2026-08-05 | $1.69B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $463.30M 10-Q · filed 2026-05-06 | $809.50M derived: sum of 2 quarters · filed 2026-05-06 | $1.37B derived: sum of 3 quarters · filed 2026-05-06 | $1.56B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $346.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $908.30M derived: sum of 2 quarters · filed 2026-02-25 | $1.10B derived: sum of 3 quarters · filed 2026-08-05 | $1.56B 10-K · filed 2026-02-25 | |
| 2025-09-30 | $562.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $753.80M derived: sum of 2 quarters · filed 2026-08-05 | $1.22B 10-Q · filed 2025-10-29 | $1.56B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $191.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $652.90M 10-Q · filed 2026-08-05 | $994.10M derived: sum of 3 quarters · filed 2026-08-05 | $1.37B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $461.20M 10-Q · filed 2026-05-06 | $802.40M derived: sum of 2 quarters · filed 2026-05-06 | $1.18B derived: sum of 3 quarters · filed 2026-05-06 | $1.41B derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $341.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $718.40M derived: sum of 2 quarters · filed 2026-02-25 | $950.60M derived: sum of 3 quarters · filed 2026-02-25 | $1.33B 10-K · filed 2026-02-25 | |
| 2024-09-30 | $377.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $609.40M derived: sum of 2 quarters · filed 2025-10-29 | $985.90M 10-Q · filed 2025-10-29 | $1.14B derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $232.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $608.70M 10-Q · filed 2025-07-30 | $759.40M derived: sum of 3 quarters · filed 2026-02-25 | $1.11B derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $376.50M 10-Q · filed 2025-04-30 | $527.20M derived: sum of 2 quarters · filed 2026-02-25 | $873.40M derived: sum of 3 quarters · filed 2026-02-25 | $979.70M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $150.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $496.90M derived: sum of 2 quarters · filed 2026-02-25 | $603.20M derived: sum of 3 quarters · filed 2026-02-25 | $978.00M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $346.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $452.50M derived: sum of 2 quarters · filed 2024-10-30 | $827.30M 10-Q · filed 2024-10-30 | $955.50M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $106.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $481.10M 10-Q · filed 2024-07-31 | $609.30M derived: sum of 3 quarters · filed 2025-02-26 | $867.90M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $374.80M 10-Q · filed 2024-05-01 | $503.00M derived: sum of 2 quarters · filed 2025-02-26 | $761.60M derived: sum of 3 quarters · filed 2025-02-26 | $888.60M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $128.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $386.80M derived: sum of 2 quarters · filed 2025-02-26 | $513.80M derived: sum of 3 quarters · filed 2025-02-26 | $802.50M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $258.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $385.60M derived: sum of 2 quarters · filed 2023-11-01 | $674.30M 10-Q · filed 2023-11-01 | $848.90M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-06-30 | $127.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $415.70M 10-Q · filed 2023-08-02 | $590.30M derived: sum of 3 quarters · filed 2024-02-21 | $775.90M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2022-03-31 | $288.70M 10-Q · filed 2023-05-03 | $463.30M derived: sum of 2 quarters · filed 2024-02-21 | $648.90M derived: sum of 3 quarters · filed 2024-02-21 | $797.10M derived: sum of 4 quarters · filed 2024-02-21 | |
| 2021-12-31 | $174.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $360.20M derived: sum of 2 quarters · filed 2024-02-21 | $508.40M derived: sum of 3 quarters · filed 2024-02-21 | $598.20M 10-K · filed 2024-02-21 | |
| 2021-09-30 | $185.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $333.80M derived: sum of 2 quarters · filed 2022-11-02 | $423.60M 10-Q · filed 2022-11-02 | $549.80M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-06-30 | $148.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $238.00M 10-Q · filed 2022-08-03 | $364.20M derived: sum of 3 quarters · filed 2023-02-22 | $615.10M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2021-03-31 | $89.80M 10-Q · filed 2022-05-04 | $216.00M derived: sum of 2 quarters · filed 2023-02-22 | $466.90M derived: sum of 3 quarters · filed 2023-02-22 | $630.90M derived: sum of 4 quarters · filed 2023-02-22 | |
| 2020-12-31 | $126.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $377.10M derived: sum of 2 quarters · filed 2023-02-22 | $541.10M derived: sum of 3 quarters · filed 2023-02-22 | $755.70M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $250.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $414.90M derived: sum of 2 quarters · filed 2021-11-03 | $629.50M 10-Q · filed 2021-11-03 | $732.00M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $164.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $378.60M 10-Q · filed 2021-08-04 | $481.10M derived: sum of 3 quarters · filed 2022-02-24 | $666.50M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $214.60M 10-Q · filed 2021-05-05 | $317.10M derived: sum of 2 quarters · filed 2022-02-24 | $502.50M derived: sum of 3 quarters · filed 2022-02-24 | $635.40M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $102.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $287.90M derived: sum of 2 quarters · filed 2022-02-24 | $420.80M derived: sum of 3 quarters · filed 2022-02-24 | -$206.60M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $185.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $318.30M derived: sum of 2 quarters · filed 2020-10-28 | -$309.10M 10-Q · filed 2020-10-28 | -$223.70M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-06-30 | $132.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | -$494.50M 10-Q · filed 2020-07-29 | -$409.10M derived: sum of 3 quarters · filed 2021-02-24 | -$171.60M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2019-03-31 | -$627.40M 10-Q · filed 2020-04-29 | -$542.00M derived: sum of 2 quarters · filed 2021-02-24 | -$304.50M derived: sum of 3 quarters · filed 2021-02-24 | -$124.70M derived: sum of 4 quarters · filed 2021-02-24 | |
| 2018-12-31 | $85.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $322.90M derived: sum of 2 quarters · filed 2021-02-24 | $502.70M derived: sum of 3 quarters · filed 2021-02-24 | $778.40M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $237.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $417.30M derived: sum of 2 quarters · filed 2019-10-30 | $693.00M 10-Q · filed 2019-10-30 | $660.00M 10-Q · filed 2018-10-31 | $607.20M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $179.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $455.50M 10-Q · filed 2019-07-31 | $369.70M derived: sum of 3 quarters · filed 2020-02-26 | $628.20M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2018-03-31 | $275.70M 10-Q · filed 2019-05-01 | $189.90M derived: sum of 2 quarters · filed 2020-02-26 | $448.40M derived: sum of 3 quarters · filed 2020-02-26 | $519.10M derived: sum of 4 quarters · filed 2020-02-26 | |
| 2017-12-31 | -$85.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $172.70M derived: sum of 2 quarters · filed 2020-02-26 | $243.40M derived: sum of 3 quarters · filed 2020-02-26 | $474.20M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $258.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $329.20M derived: sum of 2 quarters · filed 2018-10-31 | $560.00M 10-Q · filed 2018-10-31 | $723.40M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $70.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $301.50M 10-Q · filed 2018-08-01 | $464.90M derived: sum of 3 quarters · filed 2019-02-27 | $693.60M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $230.80M 10-Q · filed 2018-05-02 | $394.20M derived: sum of 2 quarters · filed 2019-02-27 | $622.90M derived: sum of 3 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $163.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $392.10M derived: sum of 2 quarters · filed 2019-02-27 | $643.60M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | $228.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $480.20M 10-Q · filed 2017-10-25 | |||
| 2016-06-30 | $251.50M 10-Q · filed 2017-07-27 | ||||
| 2015-12-31 | $382.80M 10-K · filed 2018-02-21 | ||||
| 2012-12-31 | $105.21M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $198.66M derived: sum of 2 quarters · filed 2013-02-26 | $286.04M derived: sum of 3 quarters · filed 2013-02-26 | $323.63M 10-K · filed 2013-02-26 | |
| 2012-09-30 | $93.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $180.83M derived: sum of 2 quarters · filed 2012-11-01 | $218.42M 10-Q · filed 2012-11-01 | $270.05M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2012-06-30 | $87.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $124.97M 10-Q · filed 2012-07-26 | $176.60M derived: sum of 3 quarters · filed 2013-02-26 | $257.28M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2012-03-31 | $37.59M 10-Q · filed 2012-04-26 | $89.21M derived: sum of 2 quarters · filed 2013-02-26 | $169.89M derived: sum of 3 quarters · filed 2013-02-26 | $234.43M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-12-31 | $51.63M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $132.31M derived: sum of 2 quarters · filed 2013-02-26 | $196.84M derived: sum of 3 quarters · filed 2013-02-26 | $250.19M 10-K · filed 2013-02-26 | |
| 2011-09-30 | $80.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $145.22M derived: sum of 2 quarters · filed 2012-11-01 | $198.57M 10-Q · filed 2012-11-01 | $237.82M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | $64.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $117.89M 10-Q · filed 2012-07-26 | $157.14M derived: sum of 3 quarters · filed 2013-02-26 | $259.97M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | $53.35M 10-Q · filed 2012-04-26 | $92.60M derived: sum of 2 quarters · filed 2013-02-26 | $195.43M derived: sum of 3 quarters · filed 2013-02-26 | $230.66M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2010-12-31 | $39.25M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $142.08M derived: sum of 2 quarters · filed 2013-02-26 | $177.31M derived: sum of 3 quarters · filed 2013-02-26 | $211.53M 10-K · filed 2013-02-26 | |
| 2010-09-30 | $102.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $138.06M derived: sum of 2 quarters · filed 2011-10-27 | $172.28M 10-Q · filed 2011-10-27 | $198.60M derived: sum of 4 quarters · filed 2012-02-28 | |
| 2010-06-30 | $35.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $69.45M 10-Q · filed 2011-07-28 | $95.77M derived: sum of 3 quarters · filed 2012-02-28 | $111.76M derived: sum of 4 quarters · filed 2012-02-28 | |
| 2010-03-31 | $34.22M 10-Q · filed 2011-04-28 | $60.54M derived: sum of 2 quarters · filed 2012-02-28 | $76.53M derived: sum of 3 quarters · filed 2012-02-28 | ||
| 2009-12-31 | $26.32M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $42.31M derived: sum of 2 quarters · filed 2012-02-28 | $99.72M 10-K · filed 2012-02-28 | ||
| 2009-09-30 | $15.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $73.40M 10-Q · filed 2010-10-28 | |||
| 2009-06-30 | $57.41M 10-Q · filed 2010-07-28 | ||||
| 2008-12-31 | -$40.43M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |